Cancer is a disease consisting of both genetic and epigenetic changes. Although increasing evidence demonstrates that tumour progression entails chromatin-mediated changes such as DNA methylation, the role of histone variants in cancer initiation and progression currently remains unclear. Histone variants replace conventional histones within the nucleosome and confer unique biological functions to chromatin 1-3 . Here we report that the histone variant macroH2A (mH2A) suppresses tumour progression of malignant melanoma. Loss of mH2A isoforms, histone variants generally associated with condensed chromatin and fine-tuning of developmental gene expression programs 1,4-6 , is positively correlated with increasing malignant phenotype of melanoma cells in culture and human tissue samples. Knockdown of mH2A isoforms in melanoma cells of low malignancy results in significantly increased proliferation and migration in vitro and growth and metastasis in vivo. Restored expression of mH2A isoforms rescues these malignant phenotypes in vitro and in vivo. We demonstrate that the tumour-promoting function of mH2A loss is mediated, at least in part, through direct transcriptional upregulation of CDK8. Suppression of CDK8, a colorectal cancer oncogene 7,8 , inhibits proliferation of melanoma cells, and knockdown of CDK8 in cells depleted of mH2A suppresses the proliferative advantage induced by mH2A loss. Moreover, a significant inverse correlation between mH2A and CDK8 expression levels exists in melanoma patient samples. Taken together, our results demonstrate that mH2A is a critical component of chromatin that suppresses the development of malignant melanoma, a highly intractable cutaneous neoplasm.
Cancer is a disease consisting of both genetic and epigenetic changes. Although increasing evidence demonstrates that tumour progression entails chromatin-mediated changes such as DNA methylation, the role of histone variants in cancer initiation and progression currently remains unclear. Histone variants replace conventional histones within the nucleosome and confer unique biological functions to chromatin [1] [2] [3] . Here we report that the histone variant macroH2A (mH2A) suppresses tumour progression of malignant melanoma. Loss of mH2A isoforms, histone variants generally associated with condensed chromatin and fine-tuning of developmental gene expression programs 1, [4] [5] [6] , is positively correlated with increasing malignant phenotype of melanoma cells in culture and human tissue samples. Knockdown of mH2A isoforms in melanoma cells of low malignancy results in significantly increased proliferation and migration in vitro and growth and metastasis in vivo. Restored expression of mH2A isoforms rescues these malignant phenotypes in vitro and in vivo. We demonstrate that the tumour-promoting function of mH2A loss is mediated, at least in part, through direct transcriptional upregulation of CDK8. Suppression of CDK8, a colorectal cancer oncogene 7, 8 , inhibits proliferation of melanoma cells, and knockdown of CDK8 in cells depleted of mH2A suppresses the proliferative advantage induced by mH2A loss. Moreover, a significant inverse correlation between mH2A and CDK8 expression levels exists in melanoma patient samples. Taken together, our results demonstrate that mH2A is a critical component of chromatin that suppresses the development of malignant melanoma, a highly intractable cutaneous neoplasm.
The H2A family is the largest and most diverse histone family, and includes vertebrate-specific mH2A1 (splice variants mH2A1.1 and 1.2) and mH2A2 (refs 1,3,9-11) , which are generally associated with transcriptionally repressed chromatin 12, 13 . However, mH2A is widely distributed throughout chromatin [4] [5] [6] and exists in post-translationally modified forms 3, 14 , suggesting additional unidentified functions for this variant.
Given increasing evidence for variant-mediated transcriptional control 1, 3 and recent reports describing variants as prognostic markers in cancer 15, 16 , we hypothesized that global alteration of variants could contribute to malignant melanoma, the most lethal form of skin cancer with rising incidence 17, 18 . Its radial growth phase (RGP) is characterized by lateral melanocyte growth and its vertical growth phase (VGP) by spread of melanoma cells into the dermis and subcutis, upon which metastasis can occur 19 .
Using well characterized, paired series of murine and human melanoma cells lines, we probed the H2A variant profile. The murine B16 series represents cells of increasing metastatic potential 20 , and the human series of a primary melanoma (WM115) and two subsequent skin metastases derived from this same patient (WM266-4 and WM165-1) 21 . In highly malignant cells of the murine and human series, a global decrease of mH2A1 and mH2A2 protein and messenger RNA (mRNA) was observed ( Fig. 1a and Supplementary Figs 1 and 2 ). Analysis of histones from both series using multiplexed quantitative mass spectrometry 22 confirmed these findings ( Supplementary Fig. 1 ). Furthermore, mH2A1 and mH2A2 loss was observed in a panel of primary and metastatic melanoma cells ( Supplementary Fig. 1 ). Interestingly, a 1.5-to threefold increase in H2A.Z levels (often associated with promoters of active genes) 1,3 was also observed ( Fig. 1a and Supplementary Fig. 3 ), implicating possible H2A variant exchange during melanoma progression. Consistent with a global loss of mH2A and increased H2A.Z levels, we observed highly decondensed chromatin in B16-F10 cells by micrococcal nuclease digestion (Supplementary Fig. 2 ).
Next, we performed immunohistochemistry (IHC) on approximately 115 human tissues ranging from benign nevi to metastatic melanoma (tissue set 1, Supplementary Fig. 4 ). mH2A2 antibody was used for IHC, as it produced clear nuclear staining, and tissues were independently scored (0-3) by two blinded dermatopathologists with excellent interobserver consistency (k 5 0.80). IHC demonstrated that although mH2A2 is abundant in melanocytes of benign nevi and RGP lesions, its expression is dramatically lost in more than 80% of VGP and metastatic melanomas (P , 0.001) ( Fig. 1b and Supplementary Fig. 4 ). This suggests mH2A loss occurs during the critical RGP to VGP transition. IHC was also performed on 25 melanomas with known BRAF status (D.P., unpublished observations) 23 . An activating mutation of BRAF, V600E, is present in approximately 65% of melanomas 24 . Although this data set did not reveal a significant correlation between mH2A2 loss and V600E mutation, it produced similar mH2A2 results as the first cohort, as did a tissue microarray ( Supplementary Fig. 4 ). Using fresh tissues, we observed significantly reduced levels of mH2A1 and mH2A2 mRNA in metastatic melanoma specimens compared with nevi and primary melanocytes ( Fig. 1c ).
Owing to the transcriptional downregulation of mH2A in human melanoma, combined with its re-expression in metastatic melanoma cells upon 5-Aza-29-deoxycytidine treatment ( Supplementary Fig. 5 ), we hypothesized that DNA methylation may enable silencing of mH2A. Indeed, through extensive bisulphite sequencing analysis, we identified a region of the mH2A2 promoter that is significantly methylated in metastatic melanoma tissues and cell lines, but not in primary melanocytes, WM115 cells or benign nevi ( Fig. 1d and Supplementary Fig. 5 ).
Collectively, these findings prompted us to examine the functional consequences of mH2A loss. We established multiple stable short hairpin RNA (shRNA) lines in murine B16-F0 and F1 and human WM115 melanoma cells, targeting mH2A1, mH2A2 and control a, Melanoma cells probed for H2A variants; core histones used for loading. b, IHC of human tissue with mH2A2 (left) and histone H3 (right). Original magnifications 320 and 340 are shown. mH2A2 visualized using DAB (brown) and haematoxylin (blue). Arrows depict mH2A2 staining in nonmelanocytic cells. c, qRT-PCR of mH2A1 and mH2A2 in benign nevi and melanocytes (brown circles) and metastatic melanoma (black squares); P , 0.0001 d, DNA methylation of mH2A2 promoter in nevi (n 5 6, 10-12 clones per nevus) and metastatic melanoma tissues (n 5 7, 10-14 clones per tissue); 16 CpG sites shown. Open circles (unmethylated), black circles (methylated); P values determined by Mann-Whitney U test. 
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green fluorescent protein (GFP) ( Supplementary Figs 6 and 7) . Two shRNA-transduced cell lines from mouse and human were used for indepth analysis: B16-F1 mH2A1_91 and mH2A2_25 and WM115 mH2A1_90 and mH2A2_05 (Supplementary Figs 6 and 7 for additional shRNA lines and isoform-specific knockdown). Proliferation was examined in shRNA-expressing cells by colony formation and MTS cell viability assays. The loss of mH2A increases proliferation of murine and human melanoma cells ( Fig. 2a and Supplementary Figs 6 and 7) , as well as anchorage-independent growth of WM115 cells ( Fig. 2b and Supplementary Fig. 7 ). To examine growth potential in vivo, B16-F1 shRNA cell lines were injected subcutaneously into mice; mH2A-deficient cells exhibited significantly enhanced tumour growth compared with controls ( Fig. 2c ). mH2A knockdown was confirmed by immunoblotting lysates from tumours ( Supplementary Fig. 8 ).
Because cell motility contributes to metastasis and melanocytes originate from migratory neural crest cells, shRNA lines were analysed for migratory behaviour. Loss of mH2A in murine and human cells enhanced migration through an 8-mm Transwell and the ability to close an artificial wound, compared with control cells ( Fig. 2d and Supplementary Figs 6 and 7 ). Next, murine shRNA cell lines were injected into the lateral tail veins of mice to assay metastatic potential. Fourteen days after injection, mice were killed and lungs dissected for macro-and microscopic histology ( Fig. 2e ). Lungs of mice injected with mH2A1_91 and mH2A2_25 cells showed a five-and 30-fold increase, respectively, in the number of macroscopic metastases compared with lungs from control mice ( Fig. 2e ). Haematoxylin and eosin and Ki-67 staining revealed metastatic disease with proliferation, respectively, in mH2A shRNA-expressing tumours; mH2A knockdown in lungs was confirmed by IHC ( Supplementary Fig. 8 ).
Next, mH2A expression was stably restored in malignant B16-F10 and human WM266-4 and A375 cells. The core histones H2A, mH2A1 (1.2) and mH2A2 were fused to mCherry and functional stable lines generated ( Supplementary Figs 9, 11 and 13 ). Ectopic expression of mH2A1.2 and mH2A2, but not H2A or mCherry alone, resulted in reduced proliferation (without evidence of apoptosis) and migration ( Supplementary Figs 10, 12 and 14) . Human A375 cells expressing the mCherry series were injected subcutaneously into the flanks of immunocompromised mice; expression of mH2A1.2 and mH2A2 suppressed growth ( Supplementary Fig. 14) . Furthermore, B16-F10 cells expressing mCherry fusions were injected into tail veins of mice; mH2A1.2 and mH2A2 significantly suppressed metastasis to the lungs ( Fig. 2f and Supplementary Fig. 10 ).
Given the striking phenotypes of mH2A manipulation in melanoma cells, we hypothesized that loss of mH2A may alter the transcriptional state of proliferation-and metastasis-related genes. We performed gene expression profiling using Affymetrix microarrays with B16-F1 cells (mH2A1_91, mH2A2_25 and sh_GFP). As expected for mH2A's role in fine-tuning of gene expression 4 , many genes showed a less than twofold change ( Supplementary Figs 15, 16 and 17 for Venn diagrams, heatmaps and gene ontology). Fifteen genes showed at least a twofold change, common to both shRNA lines in two independent experiments, including Integrin alpha 4 (Itga4), transcriptional regulators CDK8 (Mediator complex component) and Cited1 (CBP/p300 transactivator) (Fig. 3a) . In concordance with our data, Itga4 expression is inversely correlated with invasive potential of B16 cells 25 and expression profiling of human melanoma cells identified Cited1 loss in metastatic cells 26 . CDK8, however, is a new player in melanoma malignancy.
In concordance, CDK8 mRNA and protein levels were elevated both in murine and human cells depleted of mH2A ( Fig. 3a-c) , as well as subcutaneous tumours and lung metastases derived from mH2Adeficient lines ( Supplementary Fig. 18 ). Next we stably expressed RNA interference (RNAi)-resistant mH2A2 and H2A in the B16-F1 mH2A2_24 shRNA line, which targets the 39 untranslated region of mH2A2. Although CDK8 levels remained high in mH2A2_24 cells expressing H2A-mCherry, addition of mH2A2-mCherry rescued CDK8 expression to B16-F1 levels (Fig. 3d ). Moreover, CDK8 was downregulated in subcutaneous tumours derived from A375 cells expressing mH2A1-and mH2A2-mCherry ( Fig. 3e and Supplementary Fig. 14) .
Intrigued by transcriptional upregulation of CDK8, a colorectal cancer oncogene 7,8 , we enquired if CDK8 is a direct target of mH2A. Chromatin immunoprecipitation (ChIP) analysis demonstrated that the CDK8 promoter is enriched in mH2A1-containing nucleosomes in B16-F1, but absent in B16-F10 cells and a control shRNA line ( Fig. 3f and Supplementary Fig. 18 ). ChIP analysis of additional mH2A target genes (but not an intergenic locus or GAPDH) also revealed enrichment, and demonstrated that CDK8 is a highly enriched mH2A target gene (Fig. 3f ).
By examining a panel of human cell lines, we observed high CDK8 protein levels in metastatic melanoma cells, comparable to that of colon cancer cells (Fig. 4a ). We used shRNAs to deplete CDK8 from B16-F10 and human A375 and WM165-1 cells, which contain high levels of CDK8 ( Fig. 4b, Supplementary Figs 19 and 20) . The loss of CDK8 significantly reduced proliferation (Fig. 4b ) mediated by G2/M arrest in human cells ( Supplementary Fig. 20) . Conversely, ectopic expression of CDK8 (and a kinase-defective mutant, D173A) 7 in B16-F1 cells resulted in significantly increased proliferation (Supplementary Fig. 21 ). Although proliferation in murine melanoma cells appears independent of the kinase activity of CDK8, it may be To dissect the relationship between mH2A and CDK8, we first depleted CDK8 in mH2A shRNA-expressing cells (B16-F1 and WM115 lines). Knockdown of CDK8 was able to suppress the enhanced proliferation induced by mH2A loss in vitro and in vivo (Fig. 4c, d and Supplementary Figs 21 and 22 ). Knockdown of Med12, a subunit of the CDK8 submodule of Mediator 27 , showed a similar effect ( Fig. 4d and Supplementary Fig. 22 ), suggesting that CDK8 functions within the Mediator subcomplex in melanoma.
Next, we performed quantitative PCR with reverse transcription (qRT-PCR) of mH2A and CDK8 in 36 fresh melanoma specimens. This analysis demonstrated a statistically significant inverse correlation of mH2A2 and CDK8 at the mRNA level (Pearson's r 5 20.406; P 5 0.014; Fig. 4e ). We performed IHC for CDK8 (k 5 0.58) in human tissues previously scored for mH2A2, and observed strong CDK8 staining (scored 2-3) in a large fraction of mH2A2 negative (scored 0) melanomas (29/38 5 76%; Supplementary Fig. 23 ). A similar inverse trend was observed in a panel of human melanoma cell lines ( Supplementary Fig. 23 ). Finally, by probing fresh benign nevus tissues, we observed high mH2A and low CDK8 protein levels ( Supplementary  Fig. 23 ). Collectively, these results strongly suggest that CDK8 is a major effector of mH2A-mediated melanoma progression.
Here we demonstrate that mH2A is globally lost during melanoma progression. Similar findings have recently been described in lung cancer; mH2A1.1 is enriched in pre-cancerous senescent cells, but lost upon bypass of senescence 16 . However, the mechanism by which this occurs and its biological consequences remain unclear. Our study suggests mH2A loss in melanoma, mediated in part by DNA methylation, occurs after a potential senescence bypass (that is, in a nevus), but rather during the critical RGP to VGP transition. Nevertheless, mH2A isoforms may serve as important biomarkers for melanoma, and/or other cancers.
The data presented here point towards a novel mechanism whereby CDK8 is regulated by the unique histone variant mH2A. We look forward to future studies focused on CDK8 function and its inhibition in melanoma. Our findings support emerging links between chromatin structure and cancer, and, for the first time to our knowledge, demonstrate a direct role of mH2A in this process.
METHODS SUMMARY
Cell culture, plasmids, infections and RNAi. Detailed information is described in Methods. Chromatin fractionation, acid extraction of histones and immunoblotting. Chromatin fractionation and acid extraction of histones was performed as described 14 . Antibodies used for immunoblotting can be found in Methods. Quantitative mass spectrometry. Quantitative mass spectrometry was performed as described 22 . Immunohistochemistry, pathology and statistical analysis. Specimens were obtained from Mount Sinai School of Medicine's Division of Dermatopathology (project number HSD08-00565), New York University (IRB number 10362) and melanoma tissue microarray (Imgenex number IMH-369). Details on staining, pathology and statistical analyses are described in Methods. Clinical specimens. Human specimens were collected at the time of surgery. Approval to collect melanoma specimens was granted by Mount Sinai Biorepository Cooperative and the New York University Interdisciplinary Melanoma Cooperative Group (project numbers above). Approval to collect benign nevi was granted by Mount Sinai School of Medicine's Division of Dermatopathology (project number 08-0964). Bisulphite sequencing. This was performed according to the manufacturer's instructions (Zymo Research). Details are described in Methods. Cell proliferation, migration and mouse injections. MTS was performed according to the manufacturer's instructions (Promega). Colony formation and soft agar assays were performed as described 28 . The Transwell migration assay is described in Methods. In vivo metastasis assays were performed as described 28 . For subcutaneous injections, 2.5 3 10 5 B16-F1 cells were injected into 6-week-old C57BL/6J mice and 2 3 10 6 A375 cells injected into NOG mice (Jackson Laboratories); tumour volume measured over 14-and 20-day periods, respectively. Microarray hybridization, data analysis and hierarchical clustering. Microarray was performed using two biological replicates according to Affymetrix GeneChip protocol. Initial data extraction was performed at the Microarray Shared Research Facility at Mount Sinai School of Medicine. Heatmaps were generated using Cluster and Tree View programs. Quantitative PCR and ChIP. qPCR was performed in triplicate on Stratagene Opticon 2 using FastStart SYBR Green Mix (Roche). Expression levels were P a t ie n t 2 6 -B P a t ie n t 3 0 -A P a t ie n t 2 2 P a t ie n t 1 8 P a t ie n t 2 8 P a t ie n t 1 3 P a t ie n t 1 0 P a t ie n t 8 P a t ie n t 1 2 P a t ie n t 9 P a t ie n t 2 4 -A P a t ie n t 2 4 -B P a t ie n t 1 P a t ie n t 2 3 -B P a t ie n t 2 6 -A P a t ie n t 3 0 -B P a t ie n t 2 9 P a t ie n t 2 3 -A P a t ie n t 2 3 -C P a t ie n t 1 6 P a t ie n t 1 4 P a t ie n t 2 0 P a t ie n t 1 7 P a t ie n t 2 1 P a t ie n t 2 5 -B P a t ie n t 2 5 -A P a t ie n t 1 9 P a t ie 
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normalized to TATA binding protein or GAPDH. ChIP assays were performed using a Magna ChIP Kit (Millipore) as per the manufacturer's instructions.
probes that had at least one 'P' call in the pair were retained; (2) signal intensityonly probes that showed signal intensity of at least 100 in at least one of the pairs were retained; (3) fold change-probes that showed a log-fold change of at least 2 in at least one data set were retained for further analysis; (4) concordance analysis was performed to reduce false-positive selection between shRNA lines and the two independent microarray experiments: direction and fold-change in gene regulation had to be a 100% match to qualify as altered genes. Gene list was annotated by submission to Netaffx annotation centre within the Affymetrix website (http:// www.affymetrix.com), which periodically updates the integrated information for each gene across multiple public genome databases.
Hierarchical clustering, generation of heat maps and gene ontology analysis. A portion of the filtered subset of data was used for additional analysis. Cluster analysis was performed by unsupervised hierarchical clustering on the log-transformed data with Gene Cluster 3.0 (http://bonsai.ims.u-tokyo.ac.jp/,mdehoon/software/ cluster/index.html) by using the correlation (uncentred) similarity metric and centeroid linkage clustering method. The resulting tree-images were visualized using Java TreeView. Gene ontology analysis was performed using DAVID Bioinformatics Resources 30 (http://david.abcc.ncifcrf.gov/home.jsp).
Quantitative PCR and ChIP. Total RNA was extracted using RNeasy Kit (Qiagen). Reverse transcription was performed with SuperScript II (Invitrogen) using oligo dT. qPCR reactions were performed in triplicate on Stratagene Opticon 2 using FastStart SYBR Green Master Mix (Roche). Expression levels were normalized to TATA binding protein in mouse cells and GAPDH in human cells, or relative to B16-F1 sh_GFP for gene target expression. Each qPCR used two independent biological replicates. Primer sets used for qRT-PCR are listed in Supplementary  Table 2 . ChIP assays were performed using a Magna ChIP Kit (Protein G; Millipore) as per the manufacturer's instructions. Immunoprecipitations were performed with antibodies against mH2A1 (Millipore 07-219), H3 (Abcam ab1791) and control IgG (Millipore 12-370). ChIP signals were represented as the percentage of H3, calculated by 100 3 2 (CtH3 2 CtAntibody) . Primers used for ChIP-qPCR are listed in Supplementary Table 3 . LETTER RESEARCH
